Introduction: Continuous venovenous hemodiafiltration (CVVHDF) may alter teicoplanin pharmacokinetics and increase the risk of incorrect dosing. The objective of this prospective observational study was to assess the effect of CVVHDF on the pharmacokinetics of teicoplanin as maintenance therapy. Methods: Blood, urine, and dialysate samples were collected to measure teicoplanin levels. CVVHDF clearance (CL CVVHDF ), total clearance (CL TOTAL ), and volume of distribution (Vd) were calculated by simplex-linear modeling. The influence of CVVHDF dose on teicoplanin pharmacokinetics was assessed. Findings: Ten samples from eight patients were studied. Creatinine clearance was 3.4 AE 5.1 ml/min/1.73 m 2 . Three patients were anuria. The dose for CVVHDF was 32.1 AE 7.0 mL/kg/h. Vd was 1.6 AE 0.7 L/kg. T1/2 was 100.1 AE 42.7 hours. CL TOTAL of teicoplanin was 11.9 AE 5.4 mL/min and CL CVVHDF was 5.8 AE 4.2 mL/min. Contribution of CL CVVHDF to CL TOTAL was 51.2% AE 23.6%. CL CVVHDF of individual teicoplanin varied widely. Large intra-occasion differences were also observed. Dose of CL CVVHDF did not influence overall CL TOTAL , Vd, or half-life. The proportion of CL TOTAL due to CL CVVHDF varied widely. It was high in some cases. Discussion: In patients receiving CVVHDF, there is great variability in teicoplanin pharmacokinetics which complicates empiric approach to dosing, suggesting the need for therapeutic drug monitoring.
INTRODUCTION
The mortality rate of critically ill patients with renal replacement therapy (RRT) is very high. 1 Optimized antibiotic therapy should be considered as a key intervention to reduce mortality in this population. 2 Continuous RRT (CRRT) including continuous venovenous hemodiafiltration (CVVHDF) is widely used to treat acute kidney injury stage 3 critically ill patients. 1 Septic patients are critically dependent on adequate dose of appropriate antibiotic. Antibiotic dosing during CRRT is particularly complex because antibiotic pharmacokinetics is influenced by patient factors, drug factors, and CRRT technique. 3, 4 These variables may not lead to proper therapeutic blood concentrations, which can lead to treatment failure. 5 It is conceivable that extensive clearance of antibiotics in the context of higher CRRT dose may harm patients. 6 Despite large variability in CRRT techniques, most published clearance studies specified the prescribed CRRT dose while over half of continuous venovenous hemofiltration studies specified whether a predilution or a postdilution mode was used. 7, 8 Teicoplanin is an effective treatment for infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Teicoplanin has efficacy similar to vancomycin. It is associated with lower adverse event rate than vancomycin. 9 Although it is generally considered that trough concentration of teicoplanin should be ≥10 μg/mL for MRSA infections, it is necessary to achieve ≥15 μg/mL for MRSA to obtain high clinical efficacy of teicoplanin for MRSA infections. 10, 11 There have been several reports regarding loading dosage to achieve optimal trough concentration. 12, 13 However, pharmacokinetic studies for maintenance dosages of teicoplanin are limited. Current recommendations for patients receiving CRRT originate from either pharmacokinetic estimates of studies with a few patients and different doses of CRRT than are used today.
14,15 Insufficient current pharmacokinetic data limit evidence-based dose recommendations for patients. 3 Therefore, the objective of this prospective observational study was to evaluate the pharmacokinetics of teicoplanin as maintenance therapy in patients receiving CVVHDF with contemporary equipment and prescriptions. Effects of CVVHDF prescription on extracorporeal and systemic teicoplanin clearance (CL) and volume of distribution (Vd) were also assessed.
METHODS
This prospective observational study enrolled patients admitted to the intensive care unit (ICU) of a tertiary care medical center between September 2013 and August 2015. The study protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-MED-OBS-12-137). Written informed consent to participate in this study was obtained from each patient's legally authorized representative.
Patients selection
All adult patients aged more than 18 years admitted to the ICU who were receiving CVVHDF for oliguric or auric renal impairment were eligible for enrolment. Teicoplanin was prescribed at the discretion of treating physicians and infectious disease specialists. Teicoplanin dose and frequency were solely determined by the primary ICU service and infectious disease specialists. All patients were given a loading dose regimen (400 mg twice on Day 1 and 400 mg once on Day 2: 400 mg × 3). Serum teicoplanin concentration was determined between Day 3 and Day 15.
CVVHDF therapy
All patients were undergoing CVVHDF with post dilution mode. Vascular access was obtained with 11. 
Sample collection
Sampling was commenced at least 72 hours after concomitant CVVHDF. Patients with any interruptions in CVVHDF during the sampling period were excluded from analysis. Blood samples were collected immediately before a dose (trough) and 1 hour after the 1-hour infusion was complete (peak). Blood samples were collected in 4.5 mL plasma separator vacutainer tubes for this study. Urine and dialysate samples were collected for 24 hours after administration of maintenance dose. Dialysate and urine samples were collected in 7 mL vacutainer tubes containing no additive. Blood samples were centrifuged at 3000 rpm for 10 minutes and processed within 30 minutes of collection. All samples were stored at −20 C until they were analyzed. All samples were analyzed within 24 hours after collection in one laboratory.
Teicoplanin assay
Details the study design have been published elsewhere. 16 Briefly, concentrations of teicoplanin in plasma, urine, and effluent samples were determined using high-performance liquid chromatography with tandem mass spectrometric (LC/MS/MS system) detection methods (Applied Biosystems, Foster City, CA, USA) and column switching apparatus (Shiseido, Tokyo, Japan). A teicoplanin standard solution was prepared by dissolving the drug in distilled water at a concentration of 1 mg/mL. A sulfamethoxazole solution was prepared at a concentration of 1 μg/ml in distilled water and used as internal standard solution. Working standards were prepared by diluting standard solutions with pooled human sera, human urine, and dialysate that were free of teicoplanin. Final concentrations of 1, 2, 5, 10, 25, and 50 μg/ml were used for assessment following the assay procedure. Standard serum, urine, or dialysate (20 μL) was mixed with 10 μL of internal standards, 1% formic acid, and 0.2 mL of water and centrifuged at 12,000 rpm for 5 min. From the final filtrate volume, 2 μL of the filtrate was used for liquid chromatography analysis (Agilent 1200 system; Agilent Technologies, Santa Clara, CA, USA). The calibration curve was determined from the ratio of teicoplanin peak area to that of the internal standard sample. This validated method has been successfully applied to therapeutic drug monitoring of teicoplanin in routine clinical practice. 16 
Pharmacokinetic analysis
Based on measured concentrations, pharmacokinetic parameters Vd and T1/2 were estimated. Pharmacokinetic parameters Vd and T1/2 were estimated with a simplex nonlinear method using CAPCIL ® software (SIMKIN Inc., Gainesville, FL, USA). The Simplex method allows for fitting by least-squares procedure regardless of when the drug concentrations were obtained with respect to dosage or degree of steady state. With this method, half-life and Vd were sought to reduce differences between actual and predicted concentrations. The maximum concentration and the minimum concentration for the dosing period were observed values. We used K12 = 0.244 (hr : the central to peripheral transfer rate constant) and K21 = 0.0509 (hr : the peripheral to central transfer rate constant) for pharmacokinetic parameters analysis with two-compartment model. These K12 and K21 have been previously employed by Yamamoto et al. 15 Total clearance (CL TOTAL ) was calculated using the following equation:
Teicoplanin CVVHDF clearance (CL CVVHDF ) was calculated at each time point based on drug recovery in CRRT 
RESULTS

Patients
Eight patients with septic shock were enrolled. Their demographics, anthropometric data, illness severity, and parameters of CVVHDF at sampling are presented in Table 1 . Creatinine CL was 3.4 AE 5.1 ml/min/1.73 m 2 . Three patients were anuric. The dose of CVVHDF was 32.1 AE 7.0 mL/kg/h. ST100 dialyzer (Gambro Lundia AB, Sweden) was used in seven patients and AV600 dialyzer (Fresenius, Germany) was used in one patient.
Pharmacokinetic parameters
Pharmacokinetic parameters and influence of CVVHDF dose on CL CVVHDF are shown in Table 2 . Trough levels of teicoplanin of all patients were measured and peak levels in six patients were determined. Serum samples of two patients whose peak levels were not measured were collected on the next day to determine their trough levels to calculate pharmacokinetic parameters. For eight patients with different maintenance dose, trough levels were 9.7 AE 6.0 μg/mL. Concentration of teicoplanin in 24 hour-collected dialysate was measured for seven patients. CL CVVHDF was 51.2 AE 23.6% of CL TOTAL . The contribution of CL CVVHDF to the calculated CL TOTAL varied widely without showing significant correlation.
Inter-occasion variability in teicoplanin pharmacokinetics
Pharmacokinetic parameters for two patients (patient number 4 and 6) who provided samples on 2 days are shown in Table 3 . Clinical information of the two patients is shown in Table 2 . RRT of patient number 4 was changed from CVVHDF to conventional hemodialysis 9 days before the next sampling. Vd and T1/2 were increased from 0.5 L/kg and 84.8 hours to 1.9 L/kg and 110.0 hours, respectively. RRT of patient number 6 kept with fixed dose of CVVHDF. Vd and T1/2 were also changed. Day-to-day variability in antibiotic pharmacokinetics was noted, although this patient received a fixed dosage of CVVHDF.
Predicted optimal dosage of teicoplanin to target trough levels
Maintenance dose regimens designed to achieve trough levels of 10, 15, and 20 μg/mL are shown in Table 4 . Predicted optimal dosage of teicoplanin showed wide variations.
DISCUSSION
Pharmacokinetic variables obtained in this study revealed Vd of 1.6 AE 0.7 L/Kg, T 1/2 of 100.1 AE 42.7 hours, CL TOTAL of 11.9 AE 5.4 mL/min, and CL CVVHDF of 5.8 AE 4.2 mL/min. Contribution of CL CVVHDF to CL TOTAL was 51.2 AE 23.6%. Considering the elimination half-life in normal kidney function is 70-100 h, 17 the amount of teicoplanin eliminated in CVVHDF seems to be not dominant to remove the drug from circulation. However, the T 1/2 of 100.1 AE 42.7 hours was lower than that in patients with chronic renal insufficiency (157-567 h), 18 suggesting that higher amounts of teicoplanin could be removed by CVVHDF. In this study, the proportion of CL by CVVHDF varied widely. It was high in some cases. The prescribed dose of CVVHDF was not positively correlated with CL CVVHDF , Vd, or half-life. Inter-occasion variability was also observed. These findings might improve our understanding of inter-and intra-individual variability in the pharmacokinetics of teicoplanin when using CVVHDF. This prospective observational study evaluated the pharmacokinetics of the maintenance dose of teicoplanin in patients receiving CVVHDF with contemporary equipment and prescriptions. Concentrations of teicoplanin in serum, urine, and dialysate were directly measured to assess the effect of CVVHDF prescription on extracorporeal and systemic teicoplanin CL and Vd. Table 5 shows relationship between results of this study and those of previous studies. Pharmacokinetic parameters and recommended dosage of teicoplanin in this study are similar to data reported by Yagasaki et al. 19 and CL CVVHDF (3.69 AE 0.4 mL/min) in in vitro CVVHDF system. 15 However, we also noted a wide difference between our results and results in the work of Bellmann et al. 14 Although they did not describe renal function of their patients except daily diuresis, it appeared to be higher than our patients because their daily diuresis were 50, 1400, 2250, and 2550 mL. Their target trough levels were also high (15-25 μg/mL) and they used dialyzers with high surface area (1.2 m 2 ). Differences in residual renal function, target level, and surface area of dialyzer might have contributed to pharmacokinetic parameters and recommend doses in each study.
In CVVHDF, post dilution HDF can be associated with enhanced CL compared to similar dose ultrafiltration administered predilution. Effluent flow is anticipated to be positively correlated with effluent flow rate and CL by convection is dose dependent. This is the most efficient method of removing larger molecules. However, our results suggest that these simple and logical relationships might not be observed in clinical practice. This variability could be due to differences in CVVHDF intensities and individual difference in patient factors that might affect pharmacokinetics such as the effect of different levels of hypoalbuminemia on unbound teicoplanin concentrations and residual renal function. 3 Renal replace therapy is associated with varied removal of antibiotics known to have high affinity for proteins while only free teicoplanin can be cleared. 14, 18 Unpredictable loss of filter membrane function or partial filter clotting or membrane fouling due to higher transmembrane pressure or adsorption of antibiotic to the filter might have contributed to variable results observed. The effect of prescribed CRRT effluent flow rate on other antibiotics was not consistently dose-dependent either. 20 Such variability in CL CVVHDF limits attempts to develop dosing guidelines. The reason for this variability requires further investigation. It may include differences in renal and non-renal CL mechanisms.
We observed both inter-individual and intra-individual variability in pharmacokinetics. Hemodynamic changes 
